Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate Cancer

Phase 1

Completed

• Conditions: Prostate Cancer; Bowel toxicity; Urinary toxicity; Cancer - Prostate; Oral and Gastrointestinal - Normal oral and gastrointestinal development and function; Renal and Urogenital - Normal development and function of male and female renal and urogenital system

• Registration Number: ACTRN12612000101886
• Lead Sponsor: School of Paramedical Sciences, Shahid Beheshti Medical University,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 36

Inclusion Criteria

Patients with Prostate Cancer Candidate for External Beam Radiotherapy

Exclusion Criteria

Patients with Metastatic Prostate Cancer, Patients with Kidney & Liver dysfunction, Patients who receive any H2– Histamine receptor antagonist simultaneously, Patients with Allergic reaction in consequence of Famotidine Administration.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gastrointestinal Acute Toxicity as assessed using the RTOG Grading Criteria[every week during the treatment and one month after end of the treatment];Genitourinary Acute Toxicity as assessed using the RTOG Grading Criteria[every week during the treatment and one month after end of the treatment]

Secondary Outcome Measures

Name	Time	Method
Heme Acute Toxicity as assessed using the RTOG Grading Criteria[every two weeks during the treatment and one month after end of the treatment]